4017-32-7

Upstream product

• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 609-09-6 Diethyl ketomalonate 
• 36309-52-1 diethyl N-[(2,4-dinitrophenyl)amino]malonate 
• 36239-09-5 ethyl chlorocarbonylacetate 
• 1635-61-6 5-chloro-2-nitroaniline 
• 288841-20-3 6-chloro-2-(ethoxycarbonyl)-3-hydroxyquinoxaline-1-oxide 
• 143948-67-8 ethyl 3-(5-chloro-2-nitrophenylamino)-3-oxopropanoate 
• 685-87-0 Diethyl 2-bromomalonate 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 288841-20-3 ethyl 6-chloro-3 4-dihydro-3-oxoquinoxaline-2-carboxylate-1-oxide 
• 350796-01-9 ethyl 6-amino-3,4-dihydro-3-oxoquinoxaline-2-carboxylate 
• 59743-08-7 diethyl 2,3-dioxosuccinate 

Downstream Products

• 350795-71-0 6-chloro-3-oxo-1-p-tolylcarbamoyl-1,2,3,4-tetrahydro-quinoxaline-2-carboxylic acid ethyl ester 
• 350795-67-4 6-chloro-3-oxo-1-phenylcarbamoyl-1,2,3,4-tetrahydro-quinoxaline-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

New quinoxaline derivatives as dual pim-1/2 kinase inhibitors: Design, synthesis and biological evaluation

Proviral integration site for Moloney murine leukemia virus (Pim)-1/2 kinase overexpression has been identified in a variety of hematologic (e.g., multiple myeloma or acute myeloid leukemia (AML)) and solid (e.g., colorectal carcinoma) tumors, playing a key role in cancer progression, metastasis, and drug resistance, and is linked to poor prognosis. These kinases are thus considered interesting targets in oncology. We report herein the design, synthesis, structure–activity relationships (SAR) and in vitro evaluations of new quinoxaline derivatives, acting as dual Pim1/2 inhibitors. Two lead compounds (5c and 5e) were then identified, as potent submicromolar Pim-1 and Pim-2 inhibitors. These molecules were also able to inhibit the growth of the two human cell lines, MV4-11 (AML) and HCT-116 (colorectal carcinoma), expressing high endogenous levels of Pim-1/2 kinases.

INHIBITORS OF FATTY ACID BINDING PROTEIN

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Design, synthesis, and AMPA receptor antagonistic activity of a novel 6-nitro-3-oxoquinoxaline-2-carboxylic acid with a substituted phenyl group at the 7 position

We describe the design, synthesis, and biological properties of a novel series of 7-substituted 6-nitro-3-oxoquinoxaline-2-carboxylic acids. After designing, studying the structure-activity relationships, and evaluating the properties of various compounds

6-subtituted-7-heteroquinoxalinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both

The invention provides compounds with antagonism against excitatory amino acid receptors, in particular, AMPA receptor having 6-substituted-7-heteroquinoxalinecarboxylic acid derivatives and addition salts thereof as effective ingredients, and processes for the preparation of both. The compounds are 6-substituted-7-heteroquinoxalinecarboxylic acid derivatives represented by the formula (1) where A denotes a single bond or methylene (CH2), Y denotes a nitrogen atom or ═CH—, V denotes a single bond or methylene (CH2), T denotes a hydroxyl group, amino group, lower alkoxycarbonyl group, carboxyl group, aldehyde group or the like, Q denotes a halogen atom, lower alkyl group or lower alkoxy group, and R1denotes a hydroxyl group, lower alkoxy group or the like, and addition salts thereof.

Synthesis of a set of ethyl 1-carbamoyl-3-oxoquinoxaline-2-carboxylates and of their constrained analogue imidazo[1,5-a]quinoxaline-1,3,4-triones as glycine/NMDA receptor antagonists

The synthesis and glycine/NMDA and AMPA receptor affinities of a set of ethyl (±) 1-N-carbamoyl-1,2,3,4-tetrahydro-3-oxoquinoxaline-2-carboxylates 1-11 and those of their constrained analogue (±) 1,2,3,3a,4,5-hexahydroimidazo[1,5-a]quinoxaline-1,3,4-triones 12-24 are reported. Compounds 1-11 bear a side-chain at position 1 which has been spatially constrained in compounds 12-24. Most of the reported tricyclic derivatives 12-24 showed glycine/NMDA binding activity comparable to that of their corresponding bicyclic analogues 1-11 providing further evidence that the spatial orientation of the side-chain is an important structural requirement for glycine/NMDA receptor antagonists.

Synthesis of substituted 2-ethoxycarbonyl- and 2-carboxyquinoxalin -3 ones for evaluation of antimicrobial and anticancer activity

A series of variously substituted quinoxalin-3-ones bearing an ethoxycarbonyl or carboxy group in the C-2 position has been prepared and their structures proved by 1H NMR spectroscopy. The obtained compounds were investigated in vitro for antimicrobial and anticancer activities. Preliminary results showed a moderate activity against a few strains of bacteria but no significant anticancer and anti-HIV activity.

Quinoxaline-2-carboxamidotetrazoles

Compounds of the general formula I: STR1 and pharmaceutically acceptable salts thereof in which: A represents the group STR2 or the group STR3 linked to the adjacent benzene ring through the nitrogen atom, in which R1 represents a hydrogen atom, or an alkyl group which may optionally be substituted by one or more aryl, aryloxy, alkoxy, acyloxy, amino, alkylamino, dialkylamino or hydroxy groups or represents an alkenyl group; R2 represents a hydrogen atom, a halogen atom or an alkyl group or the group OR3, where R3 is a hydrogen atom or an alkyl group which may optionally be substituted by one or more aryl, aryloxy, alkoxy, acyloxy, hydroxy, amino, alkylamino or dialkylamino groups or the group NR4 R5 where R4 and R5 may be the same or different and have the meanings given for R1 or R4 and R5 together with the nitrogen atom form a 5 or 6 membered heterocyclic ring which may optionally contain additional hetero atoms; R6 and R7 which may be the same or different represent a hydrogen atom, or a halogen atom or an alkyl group or the group OR3 or the group NR4 R5 as defined above. These compounds have activity as for the treatment of conditions caused primarily by the combination of an antigen with a reaginic antibody.